NVDA gained a massive 197% since our AI first added it in November - is it time to sell? 🤔Read more

Early Indicators Show China Slowed for an Eighth Month in January

Published 28/01/2019, 21:00
© Bloomberg. Employees examine vials of adrenaline hydrochloride injection solution at a China Grand Pharmaceutical and Healthcare Holdings Ltd. facility in Wuhan, China, on Tuesday, June 13, 2017. China Grand Pharma mainly aims to export finished drugs to developing markets and hasn’t faced regulatory actions from the U.S. or European drug quality watchdogs, according to the company. Photographer: Qilai Shen/Bloomberg
STAN
-
HG
-
SSEC
-

(Bloomberg) -- China’s economy slowed for an eighth straight month in January, as weaker global demand and decelerating factory inflation combined to undercut growth.

That’s the signal from a Bloomberg Economics gauge aggregating the earliest-available indicators on business conditions and market sentiment. The data suggest the government’s stimulus efforts have yet to translate into more business activity so far in the first quarter, after the economy notched its slowest expansion since 2009.

“The economy is still decelerating, but at a slower pace,” said David Qu at Bloomberg Economics in Hong Kong. “Concerns over global trade and fragile confidence continue to weigh on the economy.”

The government unveiled more support for the economy in January, with the central bank cutting the amount of money banks must hold to secure liquidity and the Ministry of Finance aiming to allow provincial governments to sell more special bonds.

On the trade front, Vice Premier Liu He heads to Washington this week for a pivotal round of talks focused on resolving the confidence-sapping trade war with the U.S. With the two sides still falling short on key “structural issues” such as intellectual property protection, there’s little sign that a breakthrough before March, when the current truce is set to end, is likely.

Official Data

The first official economic data for January, the purchasing managers indexes for the manufacturing and non-manufacturing sectors, will be released Thursday morning in Beijing.

The manufacturing gauge will probably stay below the 50 level that denotes contraction, according to economists polled in a Bloomberg survey. In December, the PMI dropped to 49.4, the weakest since early 2016. The non-manufacturing gauge, which covers construction and services, is forecast to stay unchanged at 53.8, according to the survey.

China’s manufacturing companies are already under pressure with shrinking profits and decelerating factory inflation. If the current trade talks fail, higher U.S. tariffs would further damage their prospects.

An index of business confidence among small and mid-sized enterprises maintained by Standard Chartered (LON:STAN) nudged up to 54.9 in January from 54.7 in December, lifted a tad by the government’s efforts to secure credit to the private sector.

Real activity of firms, including sales and production, continue to face downward pressure in January due to a slowing economy and the coming festive season, according to Shen Lan, the Beijing-based economist in charge of the bank’s survey.

Data from China’s major trading partners point to waning external tailwinds. The weighted average of the flash PMI readings of nations including the U.S., the European Union and Japan moderated for a ninth straight month in January. Though still in expansion territory, it was the lowest level in two years.

Other market sentiment gauges also showed that the outlook remains soft. The Shanghai Composite Index is struggling to recover from one of its worst-ever years in 2018. Prices of commodities sent a mixed message, with copper falling in January and iron ore trading rebounding from December’s lows.

A more optimistic note, for now, is coming from the labor market.

"The labor market does not show signs of a collapse and salary growth has picked up," Shen wrote. Credit access and surplus cash conditions also improved, but the borrowing rates for smaller businesses are still “elevated” even as “the money market rate trends lower on flush liquidity, suggesting the interest-rate transmission mechanism continues to impede the real economy,” she wrote.

To contact Bloomberg News staff for this story: Miao Han in Beijing at mhan22@bloomberg.net;Chloe Whiteaker in Hong Kong at cwhiteaker@bloomberg.net

To contact the editors responsible for this story: Jeffrey Black at jblack25@bloomberg.net, Sharon Chen

©2019 Bloomberg L.P.

© Bloomberg. Employees examine vials of adrenaline hydrochloride injection solution at a China Grand Pharmaceutical and Healthcare Holdings Ltd. facility in Wuhan, China, on Tuesday, June 13, 2017. China Grand Pharma mainly aims to export finished drugs to developing markets and hasn’t faced regulatory actions from the U.S. or European drug quality watchdogs, according to the company. Photographer: Qilai Shen/Bloomberg

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.